Published in Clinical Oncology Week, June 26th, 2006
The licensed indication includes patients who were less than 21 years at the time of initial diagnosis of their leukemia.
"This is a momentous day for children suffering from ALL and the doctors who treat them," said Hugh Griffith, Bioenvision's chief operating officer. "By approving Evoltra in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.